November 2026
New Lilly and Gilead funding supports therapeutic characterization
Two new sources of support totaling approximately $500,000 advance our work on nucleic acid therapeutics and biomolecular stability.
The Gadkari Research Group has received two new sources of research support totaling approximately $500,000. Together, they expand our work at the intersection of native mass spectrometry, ion mobility, and therapeutic characterization.
Lilly Research Award Program
An award through the Lilly Research Award Program (LRAP) from Eli Lilly and Company will support development of native MS and ion mobility methods for characterizing nucleic acid therapeutics. LRAP connects academic research with Lilly’s scientific expertise to advance collaborative discovery.
Gilead Sciences research agreement
A new Research Agreement with Gilead Sciences will support collaboration on correlating solution- and gas-phase measurements of unfolding and stability. This work will strengthen connections between complementary approaches to biomolecular characterization.
We are grateful for this support and look forward to the research it will enable.
Learn about Lilly’s research partnerships · Explore our research
